R&G PharmaStudies Co., Ltd. (SHE:301333)

China · Delayed Price · Currency is CNY

67.63

-0.99 (-1.44%)

At close: Apr 21, 2026

50.09% (1Y)

Market Cap	6.49B +28.8%
Revenue (ttm)	851.01M +14.4%
Net Income	136.90M -2.4%
EPS	1.43 -2.7%
Shares Out	95.99M
PE Ratio	47.29
Forward PE	39.09
Dividend	0.16 (0.23%)
Ex-Dividend Date	Jul 8, 2025

Volume	1,201,671
Average Volume	2,609,339
Open	68.63
Previous Close	68.62
Day's Range	66.94 - 69.40
52-Week Range	43.05 - 91.78
Beta	0.70
RSI	54.47
Earnings Date	Mar 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquart... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 2,208

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301333

Full Company Profile

Financial Performance

In 2025, R&G PharmaStudies's revenue was 851.01 million, an increase of 14.38% compared to the previous year's 744.00 million. Earnings were 136.90 million, a decrease of -2.37%.

Financial Statements